Search

Search Results

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  1967

  PDF: 1579

  HTML: 344

• RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

  Julie Schanz, Friederike Braulke, Detlef Haase

  e2015034

  2015-04-23

  https://doi.org/10.4084/mjhid.2015.034

  3620

  PDF: 1598

  HTML: 11465

  Figures Haase: 173

• DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES

  Prof. Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso

  e2022030

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.030

  1283

  HTML: 362

  PDF: 787

• A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY

  Flavia Mayer, Laura Faglioni, Nera Agabiti, Susanna Fenu, Francesco Buccisano, Roberto Latagliata, Roberto Ricci, Maria Antonietta Aloe Spiriti, Caterina Tatarelli, Massimo Breccia, Giuseppe Cimino, Luana Fianchi, Svitlana Gumenyuk, Stefano Mancini, Luca Maurillo, Carolina Nobile, Pasquale Niscola, Anna Lina Piccioni, Agostino Tafuri, Giulio Trapè, Alessandro Andriani, Paolo De Fabritis, Maria Teresa Voso, Marina Davoli, Gina Zini

  e2017046

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.046

  2540

  PDF: 949

  HTML: 1092

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4051

  PDF: 1419

  HTML: 569

• CLINICO-PATHOLOGICAL SPECTRUM AND NOVEL KARYOTYPIC FINDINGS IN MYELODYSPLASTIC SYNDROME: EXPERIENCE OF TERTIARY CARE CENTRE IN INDIA.

  Ruchi Gupta, Khaliqur Rahman, Manish Kumar Singh, Surabhi Kumari, Geeta yadav, Soniya Nityanand

  e2017048

  2017-08-16

  https://doi.org/10.4084/mjhid.2017.048

  1905

  PDF: 745

  HTML: 929

  Untitled: 187

• IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME

  Rosangela Invernizzi, Federica Quaglia, Matteo Giovanni Della Porta

  e2015035

  2015-04-26

  https://doi.org/10.4084/mjhid.2015.035

  3202

  PDF: 2217

  HTML: 23288

  Untitled: 183

  Untitled: 187

  Untitled: 208

• DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.

  Matteo Della Porta, Cristina Picone

  e2017017

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.017

  4644

  PDF: 1736

  HTML: 2094

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  1859

  PDF: 703

  HTML: 677

• MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY

  Emanuele Angelucci, Silvana Anna Maria Urru, Federica Pilo, Alberto Piperno

  e2017021

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.021

  3300

  PDF: 1252

  HTML: 1845

  Fig.1: 178

  Fig. 2: 186

• THERAPY-RELATED MYELOID NEOPLASMS IN CHRONIC LYMPHOCYTIC LEUKEMIA AND WALDENSTROM MICROGLOBULINEMIA

  Francesca Ricci, Alessandra Tedeschi, Marco Montillo, Enrica Morra

  e2011031

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.031

  2184

  PDF: 898

  HTML: 2346

• RECENT ADVANCES IN THE 5Q- SYNDROME

  Andrea Pellagatti, Jacqueline Boultwood

  e2015037

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.037

  2674

  PDF: 1734

  HTML: 3628

  Pellagatti Fig 1: 182

  Pellagatti Fig. 2: 182

• REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE

  Emmanuel Gyan, François Dreyfus, Pierre Fenaux

  e2015018

  2015-02-13

  https://doi.org/10.4084/mjhid.2015.018

  12225

  PDF: 1626

  HTML: 4139

  Cover letter: 177

  Figure 1: 171

• ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME

  Teresa L Field, Claudio Anasetti

  e2010019

  2010-07-19

  https://doi.org/10.4084/mjhid.2010.019

  1257

  PDF: 564

  HTML: 1172

• THROMBOCYTOPENIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - STILL AN UNSOLVED PROBLEM

  May Basood, Howard S. Oster, Moshe Mittelman

  e2018046

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.046

  2956

  PDF: 1329

  HTML: 499

• miR-155-5p PROMOTES CD34+ APOPTOSIS AND INHIBITS BONE MARROW HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY RAC1/CREB/MIR-15B AXIS

  Meiwan Cao, BaoLing Peng, WanFu Xu, PeiYu Chen, Huan Chen, LiPing Ye, Jing Xie, HongLi Wang, Lu Ren, LiYa Xiong, JingNan Zhu, XiangYe Xu, LanLan Geng, SiTang Gong

  e2023040

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.040

  659

  PDF: 783

  PDF Supp. Files: 68

  HTML: 170

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  1928

  PDF: 731

  HTML: 3098

• PERPHERAL BLOOD CELL MITOCHONDRIAL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMECAN BE IMPROVED BY A COMBINATION OF COENZYME Q10 AND CARNITINE Blood cell mitochondrial dysfunction in myelodysplastic syndrome

  Kalman Filanovsky, Michal Haran, Vita Mirkin, Andrei Braester, Olga Shevetz, Anfisa Stanevsky, Erica Sigler, Ekaterina Votinov, Yehudit Zalzman-Amir, Alain Berrebi, Atan Gross, Lev Shvidel

  e2020072

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.072

  997

  PDF: 729

  HTML: 268

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  2727

  PDF: 974

  HTML: 5495

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4197

  PDF: 1690

  HTML: 1094

• THE RISK OF THERAPY-RELATED MYELODYSPLASIA/ACUTE MYELOID LEUKEMIA IN HODGKIN LYMPHOMA HAS SUBSTANTIALLY DECREASED IN THE ABVD ERA ABOLISHING MECHLORETHAMINE AND PROCARBAZINE AND LIMITING VOLUMES AND DOSES OF RADIOTHERAPY

  Ercole Brusamolino, Manuel Gotti, Valeria Fiaccadori

  e2012022

  2012-04-06

  https://doi.org/10.4084/mjhid.2012.022

  2113

  PDF: 843

  HTML: 1901

• ASSOCIATION BETWEEN LEUKEMIC EVOLUTION AND UNCOMMON CHROMOSOMAL ALTERATIONS IN PEDIATRIC MYELODYSPLASTIC SYNDROME

  Viviane Lamim Lovatel, Beatriz Ferreira da Silva , Eliane Ferreira Rodrigues , Maria Luiza Rocha da Rosa Borges , Rita de Cássia Barbosa Tavares, Ana Paula Silva Bueno, Elaine Sobral da Costa, Terezinha de Jesus Marques , Teresa de Souza Fernandez

  e2024003

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.003

  1118

  PDF: 1327

  HTML: 111

• THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS

  Alessia Bari, Luigi Marcheselli, Raffaella Marcheselli, Eliana Valentina Liardo, Samantha Pozzi, Stefano Sacchi

  e2011065

  2011-12-20

  https://doi.org/10.4084/mjhid.2011.065

  2498

  PDF: 701

  HTML: 2281

• Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation Inflammatory marker elevation in MDS

  Howard Oster, Ekaterina Sklyar, Noa Golsdshmidt, Moshe Mittelman

  e2023044

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.044

  803

  PDF: 615

  HTML: 186

• Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

  Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain

  e2010012

  2010-05-31

  https://doi.org/10.4084/mjhid.2010.012

  1001

  PDF: 667

  HTML: 331

• PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY

  Alfredo Molteni, Emanuele Ravano, Marta Riva, Michele Nichelatti, Laura Bandiera, Lara Crucitti, Mauro Truini, Roberto Cairoli

  e2019015

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.015

  1751

  PDF: 947

  HTML: 286

• THERAPY-RELATED MYELOID NEOPLASMS IN PATIENTS TREATED FOR HODGKIN LYMPHOMA

  Dennis A Eichenauer, Andreas Engert

  e2011046

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.046

  2208

  PDF: 708

  HTML: 1170

• Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity

  Eleftheria Lamprianidou, Chryssoula Kordella, Menelaos Papoutselis, Zoi Bezyrgiannidou, Evangelia Nakou, Spyros Papamichos, Emmanouil Spanoudakis, Andreas Giannopoulos, Katerina Zoi, Ioannis Kotsianidis

  e2017066

  2017-11-01

  https://doi.org/10.4084/mjhid.2017.066

  2194

  PDF: 733

  HTML: 775

• THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies

  Emine Atli, Rasime Kalkan, Cisem Mail, Damla Eker, Ufuk Demirci, Selma Demir, Sinem Yalcintepe, Hakki Onur Kirkizlar, Engin Atli, Hakan Gurkan, Ahmet Muzaffer Demir

  e2021013

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.013

  1415

  PDF: 498

  HTML: 238

• Clinical and Prognostic Features in a Young Adult Patient with de novo Myelodysplastic Syndrome presenting t(11;16) (q23; q24)

  Viviane Lamim Lovatel, Luize Otero, Ercole Pietro Orlando, Claudia Diniz, Filipe Vicente dos Santos-Bueno, Bruno Almeida Lopes, Elaiza Almeida Antônio de Kós, Monica Kopischitz Praxedes Lusis, Eliana Abdelhay, Teresa de Souza Fernandez

  e2022013

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.013

  1031

  PDF: 509

  HTML: 207

• DECREASED CD10 EXPRESSION IN THE BONE MARROW NEUTROPHILS OF HIV POSITIVE PATIENTS

  Annemarie Van de Vyver, Adele Visser

  e2010032

  2010-11-10

  https://doi.org/10.4084/mjhid.2010.032

  1182

  PDF: 831

  HTML: 1092

  Coverletter: 172

• A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management

  Elena Elli, Caterina Cecchetti, Angelo Belotti, Lorenza Borin, Enrico Maria Pogliani

  e2012017

  2012-03-13

  https://doi.org/10.4084/mjhid.2012.017

  1102

  PDF: 639

  HTML: 726

• Should every patient with MDS get iron chelation – probably yes.

  Kanjaksha Ghosh, Emanuele Angelucci, Federica Pilo, Kinjalka Ghosh

  e2017055

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.055

  2240

  PDF: 916

  HTML: 355

• HAPLOIDENTICAL TRANSPLANT WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE FOR ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASTIC SYNDROMES PATIENTS: THE ROLE OF PREVIOUS LINES OF THERAPY.

  Daniele Avenoso, Fabio Serpenti, Liron Barnea Slonim, Styliani Bouziana, Francesco Dazzi, Guy Hannah, Michelle Kenyon, Varun Mehra, Austin Kulasekararaj, Pramila Krishnamurthy, Mili Naresh Shah, Sharon Lionel, Antonio Pagliuca, Victoria Potter

  e2024002

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.002

  1180

  PDF: 1398

  HTML: 139

• FLUDARABINE-BASED LOW-INTENSITY CONDITIONING FOR FANCONI ANEMIA IS ASSOCIATED WITH GOOD OUTCOMES IN APLASTIC ANEMIA BUT NOT IN MDS - A SINGLE-CENTER EXPERIENCE

  Biju George, Sohini Chattopadhyay, Sharon Lionel, Sushil Selvarajan, Anup Devasia, Anu Korula, Uday Kulkarni, Fouzia Aboobacker, Eunice Sindhuvi, Kavitha Lakshmi, Alok Srivastava, Aby Abraham, Vikram Mathews

  e2023039

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.039

  1192

  PDF: 929

  HTML: 289

• GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS

  Angela Stoddart, Megan E. McNerney, Elizabeth Bartom, Rachel Bergerson, David J. Young, Zhijian Qian, Jianghong Wang, Anthony A. Fernald, Elizabeth M. Davis, Richard A. Larson, Kevin P. White, Michelle M. Le Beau

  e2011019

  2011-05-16

  https://doi.org/10.4084/mjhid.2011.019

  2511

  PDF: 770

  HTML: 5172

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2054

  PDF: 696

  HTML: 1609

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2396

  PDF: 757

  HTML: 1720

• GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE

  Francesco Fabozzi, Angela Mastronuzzi

  e2023032

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.032

  1815

  PDF: 470

  HTML: 496

• Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in a Child with Myelodysplastic Neoplasm with Complex Karyotype and ETV6 Variant: Challenges in Treatment

  Elaiza Almeida Antônio de Kós , Viviane Lamim Lovatel , Rita de Cássia Barbosa Tavares , Gerson Moura Ferreira , Bernadete Evangelho Gomes, Ana Paula Silva Bueno, Elaine Sobral da Costa , Teresa de Souza Fernandez

  e2024040

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.040

  731

  PDF: 931

  HTML: 79

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2033

  PDF: 1117

  HTML: 1966

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.

  Elisabetta Metafuni, Patrizia Chiusolo, Luca Laurenti, Federica Sorà, Sabrina Giammarco, Andrea Bacigalupo, Giuseppe Leone, Simona Sica

  e2018005

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.005

  4079

  PDF: 1012

  HTML: 1147

• BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN

  Maria Teresa Voso, Giulia Falconi, Dr. Fabiani

  e2023055

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.055

  1674

  PDF: 924

  HTML: 126

• THE GROWING ROLE OF THE BH3 MIMETIC DRUG VENETOCLAX IN THE THERAPY OF ACUTE MYELOID LEUKEMIA

  Elvira Pelosi, Dr. Germana Castelli, Ugo Testa

  e2022080

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.080

  1353

  PDF: 1081

  HTML: 239

• Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited

  IOANNIS KOTSIANIDIS

  e2019045

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.045

  1050

  PDF: 814

  HTML: 219

• CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2022069

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.069

  1833

  PDF: 818

  HTML: 1238

• Anemia in the elderly: not always what it seems.

  Marco Cerrano, Elena Crisà, Valentina Giai, Mario Boccadoro, Dario Ferrero

  e2016017

  2016-02-25

  https://doi.org/10.4084/mjhid.2016.017

  3226

  PDF: 985

  HTML: 1751

  Figure 1: 156

  Figure 1 revised: 159

• INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER

  Caterina Giovanna Valentini, Luana Fianchi, Maria Teresa Voso, Morena Caira, Giuseppe Leone, Livio Pagano

  e2011069

  2011-12-22

  https://doi.org/10.4084/mjhid.2011.069

  3142

  PDF: 900

  HTML: 2923

• Acquired Sideroblastic Anemia: An exploratory Comparative Statistical Analysis Between Clonal and Non-clonal cases Acquired Sideroblastic Anemia

  Dina Sameh Soliman, Samah Kohla, Shehab Fareed, Susanna Akiki , Aliaa Amer, Ibrahim Ganwo, Prem Chandra, Halima El-Omri, Feryal Ibrahim

  e2022067

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.067

  862

  PDF: 542

  HTML: 304

• PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER “GOOD RISK” ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM

  Richard A. Larson, Michelle Le Beau

  e2011032

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.032

  2723

  PDF: 870

  HTML: 1848